Voyager Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference
January 04, 2023 07:00 ET
|
Voyager Therapeutics, Inc.
CAMBRIDGE, Mass., Jan. 04, 2023 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to breaking through barriers in gene therapy and neurology, today...
Voyager Therapeutics Appoints Grace E. Colón, Ph.D., to its Board of Directors
December 14, 2022 07:00 ET
|
Voyager Therapeutics, Inc.
CAMBRIDGE, Mass., Dec. 14, 2022 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to breaking through barriers in gene therapy and neurology, today...
Voyager Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
November 29, 2022 16:01 ET
|
Voyager Therapeutics, Inc.
CAMBRIDGE, Mass., Nov. 29, 2022 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to breaking through barriers in gene therapy and neurology, has...
Voyager Therapeutics Reports Third Quarter 2022 Financial and Operating Results
November 08, 2022 07:00 ET
|
Voyager Therapeutics, Inc.
- Voyager’s TRACERTM capsid platform validated by Pfizer option exercise - - Data characterizing a novel receptor and demonstrating low-dose potential further validate TRACER - - Pipeline programs...
Voyager Therapeutics Announces Third Quarter 2022 Conference Call and Webcast
November 01, 2022 07:30 ET
|
Voyager Therapeutics, Inc.
CAMBRIDGE, Mass., Nov. 01, 2022 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a gene therapy and neuroscience company developing life-changing treatments and next-generation...
Voyager Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
October 18, 2022 16:01 ET
|
Voyager Therapeutics, Inc.
CAMBRIDGE, Mass., Oct. 18, 2022 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a gene therapy and neuroscience company developing life-changing treatments and next-generation...
Voyager Therapeutics Presents Data Characterizing a Novel CNS Receptor and Demonstrating the Low-Dose Potential of TRACER™ Generated Capsid Families
October 11, 2022 07:00 ET
|
Voyager Therapeutics, Inc.
- Data presented at European Society of Gene & Cell Therapy (ESGCT) Congress 2022 - - Receptor findings support potential for human translation of Voyager’s capsids and may help overcome barriers...
Voyager Therapeutics Announces Pfizer License of Next-Generation AAV Capsid for Rare Neurologic Disease Target
October 04, 2022 07:00 ET
|
Voyager Therapeutics, Inc.
Option exercise triggers $10 million payment to Voyager, further validating the potential of the TRACER capsid platform Voyager eligible for up to $290 million in associated development, regulatory,...
Voyager Therapeutics Announces Data Presentations at the 29th Annual Congress of the European Society of Gene & Cell Therapy
October 03, 2022 07:00 ET
|
Voyager Therapeutics, Inc.
CAMBRIDGE, Mass., Oct. 03, 2022 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a gene therapy and neuroscience company developing life-changing treatments and next-generation...
Voyager Therapeutics to Participate in Upcoming Investor Conferences
September 27, 2022 07:00 ET
|
Voyager Therapeutics, Inc.
CAMBRIDGE, Mass., Sept. 27, 2022 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a gene therapy and neuroscience company developing life-changing treatments and next-generation...